期刊
NATURE MEDICINE
卷 15, 期 4, 页码 380-383出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nm.1942
关键词
-
资金
- US National Institutes of Health [HL88635, HL71670, HL49989]
- American Heart Association Established Investigator Award [0840071N]
- Australian Research Council [DP0557780]
- New South Wales Health through Hunter Medical Research Institute
- Leducq Foundation [05CVD01]
- Alberta Heart and Stroke Foundation Chair
- Australian Research Council [DP0557780] Funding Source: Australian Research Council
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a potentially lethal inherited arrhythmia syndrome in which drug therapy is often ineffective. We discovered that flecainide prevents arrhythmias in a mouse model of CPVT by inhibiting cardiac ryanodine receptor-mediated Ca2+ release and thereby directly targeting the underlying molecular defect. Flecainide completely prevented CPVT in two human subjects who had remained highly symptomatic on conventional drug therapy, indicating that this currently available drug is a promising mechanism-based therapy for CPVT.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据